Current through Register Vol. XLI, No. 38, September 20, 2024
24.1. Every person
admitted to a MAT program shall receive program orientation. The orientation
shall be made verbally at the earliest opportunity at which the patient is
stable and capable of understanding and retaining the information presented.
Information provided in the orientation shall be given to the patient in
writing at the time the decision is made to admit the patient, regardless of
his or her condition, and shall include a formal agreement of informed consent
to be signed by the patient.
24.2.
Orientation shall include the following:
24.2.a. An explanation of the rights and
responsibilities of the patient.
24.2.b. An explanation of the patient's right
to file a grievance and applicable appeal procedures.
24.2.c. An explanation of the services and
activities provided by the MAT program, either onsite or by referral,
including:
24.2.c.1. Expectations and
rules;
24.2.c.2. Hours of
operation;
24.2.c.3. Access to
after-hours services;
24.2.c.4.
Confidentiality policy;
24.2.c.5.
Drug screening and random drug-testing policies;
24.2.c.6. Sanctions, restrictions and other
penalties;
24.2.c.7.
Interventions;
24.2.c.8.
Incentives; and
24.2.c.9. Various
discharge criteria, including, but not limited to, administrative and medical
withdrawal policies and procedures.
24.2.d. An explanation about obtaining
reports from the Controlled Substances Monitoring Program database; how the
reports are used to treat and monitor the patient and the requirement that the
reports be maintained in the patient files.
24.2.e. An explanation of any and all
financial obligations of the patient; all fees charged by the MAT program; and
any financial arrangements for services provided by the MAT program, including
the requirements stated in W. Va. Code §
16-5Y-5(e).
24.2.f. Familiarization with the MAT program
facility and premises.
24.2.g. A
description of the MAT program's policies regarding:
24.2.g.1. Use of alcohol on or prior to
entering the facility and premises;
24.2.g.2. Smoking;
24.2.g.3. Illicit or licit drugs brought into
the program or onto the premises; and
24.2.g.4. Weapons brought into the program or
onto the premises.
24.2.h. Identification of the counselor
assigned to the patient and contact information for that counselor.
24.2.i. A copy of the MAT program rules
identifying the following:
24.2.i.1. Any
restrictions the program may place on the patient;
24.2.i.2. Events, behaviors or attitudes that
may lead to the loss of rights or privileges for the patient; and
24.2.i.3. Means by which the patient may
regain rights or privileges that have been restricted;
24.2.j. An explanation of the purpose and
process of the initial and subsequent physical and biopsychosocial
assessments;
24.2.k. A description
of how the individualized treatment plan of care and coordination of care
agreement will be developed and the patient's expected participation in the
plan of care; and
24.2.l. An
explanation of alternative methods that are available for treatment of
substance use disorder, whether offered by the program or not, and the
potential benefits and risks.
24.3. Upon admission, each patient shall
receive the following written information:
24.3.a. Signs and symptoms of overdose and
when, where and how to seek emergency assistance;
24.3.b. A formal agreement of informed
consent to be signed by the patient;
24.3.c. A signed copy the coordination of
care agreement;
24.3.d. Patient's
rights;
24.3.e. Confidentiality
policies;
24.3.f. The program's
processes for dispensing medication; and
24.3.g. Information on alternative methods
available for treatment of substance use disorder and the potential benefits
and risks. The state opioid treatment authority is responsible for providing
informational materials to be used in discussing alternative
treatments.
24.4. As soon
as the patient is stable and capable of understanding, the patient shall
receive group or individual education on the following:
24.4.a. Medication administration, including
methods of dispensing and dosage restrictions;
24.4.b. The nature of substance use disorder
including the great likelihood that substance use disorder is a relapsing
disease and is likely to have grave medical and social consequences if not
treated on an ongoing basis;
24.4.c. The anticipated benefits of
treatment;
24.4.d. The nature of
the recovery process;
24.4.e. HIV
spectrum and other infectious diseases;
24.4.f. Potential drug
interactions;
24.4.g. Self-help
groups;
24.4.h. Medical issues
related to detoxification from medication-assisted treatment
medications;
24.4.i. The special
risk of withdrawal from the medication-assisted treatment medication prescribed
to the individual patient and detoxification to pregnant women and the fetus,
as appropriate;
24.4.j.
Characteristics of the medications administered or prescribed by the
program;
24.4.k. Drug safety
issues;
24.4.l. Dispensing
procedures; and
24.4.m. Side
effects of medications administered or prescribed by the program.
24.5. Documentation that the
patient has completed the orientation training shall be completed and signed by
the patient and maintained in the patient's chart and individualized treatment
plan of care.